

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Roggen et al

Application No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: December 8, 2000

Examiner: To Be Assigned

For: High Throughput Screening (HTS) Assays

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE SPECIFICATION:

At page 1, after the title, insert

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. 119 of Danish application no. PA 1999 01765 filed December 9, 1999 and U.S. provisional application no. 60/170,743 filed December 14, 1999, the contents of which are fully incorporated herein by reference.

IN THE CLAIMS:

Please cancel claims 21-68 without prejudice or disclaimer.

Please amend claim 4 as follows:

At line 1, delete "claims 1-3" and insert --claim 1--.

Please amend claim 5 as follows:

At line 1, delete "claims 1-4" and insert --claim 1--.

Please amend claim 6 as follows:

At line 1, delete "claims 1-2" and insert --claim 1--.

Please amend claim 8 as follows:

At line 1, delete "claims 1-7" and insert --claim 1--.

Please amend claim 13 as follows:

At line 1, delete "claims 1-7" and insert --claim 1--.

Please amend claim 14 as follows:

At line 1, delete "claims 1-13" and insert --claim 1--.

Please amend claim 17 as follows:

At line 1, delete "claims 1-13" and insert --claim 1--.

REMARKS

This amendment is submitted to correct improper multiple dependent claims. Since only dependencies are altered, there is no new matter added, and entry of the amendment is respectfully requested.

Respectfully submitted,



Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Date: December 8, 2000